Clinical Trial

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-07-26; most recent amendment 2026-01-14.
Status change: Completed → Active, Not Recruiting 2026-01-14
Status change: Active, Not Recruiting → Completed 2025-06-12
Trial Details
NCT Number NCT05478551
Lead Sponsor Henry Ford Health System
Conditions Scar, Hypertrophic Scar
Enrollment 12 participants
Start Date 2022-06-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-15